Allergy Drug Development Report
Download the Beacon Allergies Report to stay updated on the latest developments in the field. Interest in allergies has grown exponentially and the report covers the latest findings.
Don’t miss out on valuable insights for your drug development strategies.
The report includes:
- An in-depth analysis of the current allergy trial landscape showcasing the shifts in focus and development phases.
- Beacon Immune Tolerance is currently keeping a record of 226 drugs that are being studied for allergies. The report provides detailed information on the drugs being investigated for each specific type of allergy.
- The report explores the formulation of allergy drugs. Injection is the preferred formulation, but oral formulations are gaining traction due to high compliance and cost-effectiveness.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
